Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
Public ClinicalTrials.gov record NCT00068211. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered IV daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate for all patients who are treated with ILX651. The secondary objectives are to determine the progression free survival at 18 weeks, duration of response, time to tumor progression, survival, safety/tolerability of ILX651 and to evaluate the pharmacokinetic profile.
Study identification
- NCT ID
- NCT00068211
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Jan 2006 (Actual)
- Last update posted
- Mar 5, 2015
2003 – 2006
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center at Scottsdale | Scottsdale | Arizona | 85285 | — |
| Univ of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| USC / Norris Cancer Center | Los Angeles | California | 90033 | — |
| Cancer Institute Medical Group | Santa Monica | California | 90404 | — |
| Univ of Colorado Cancer Center/ Anschutz Cancer | Aurora | Colorado | 80010 | — |
| US Oncology / Cancer Centers of Florida | Orlando | Florida | 32806 | — |
| US Oncology / Kansas City Oncology | Overland Park | Kansas | 66210 | — |
| Beth Israel Medical Center | Boston | Massachusetts | 02215 | — |
| US Oncology / Kansas City Oncology and Hematology | Kansas City | Missouri | 64111 | — |
| Center for Cancer Care Research | St Louis | Missouri | 63141 | — |
| US Oncology / Albany Regional Cancer Center | Albany | New York | 12208 | — |
| US Oncology / Dayton Oncology and Hematology | Kettering | Ohio | 45409 | — |
| US Oncology / Cancer Centers of the Carolinas | Greenville | South Carolina | 29615 | — |
| US Oncology / Mary Crowley Medical Research | Dallas | Texas | 75246 | — |
| US Oncology /Texas Oncology | Fort Worth | Texas | 76104 | — |
| St. Luke's Episcopal Hospital | Houston | Texas | 77030 | — |
| US Oncology/ Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| US Oncology / Cancer Care Northwest | Spokane | Washington | 99218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00068211, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2015 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00068211 live on ClinicalTrials.gov.